284 related articles for article (PubMed ID: 34772733)
21. Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
Wang SS; Hsiao R; Limpar MM; Lomahan S; Tran TA; Maloney NJ; Ikegaki N; Tang XX
Int J Mol Med; 2014 Jan; 33(1):35-42. PubMed ID: 24190252
[TBL] [Abstract][Full Text] [Related]
22. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
[TBL] [Abstract][Full Text] [Related]
23. RNA Binding to CBP Stimulates Histone Acetylation and Transcription.
Bose DA; Donahue G; Reinberg D; Shiekhattar R; Bonasio R; Berger SL
Cell; 2017 Jan; 168(1-2):135-149.e22. PubMed ID: 28086087
[TBL] [Abstract][Full Text] [Related]
24. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.
Wang SP; Tang Z; Chen CW; Shimada M; Koche RP; Wang LH; Nakadai T; Chramiec A; Krivtsov AV; Armstrong SA; Roeder RG
Mol Cell; 2017 Jul; 67(2):308-321.e6. PubMed ID: 28732206
[TBL] [Abstract][Full Text] [Related]
25. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic Dysregulation in
Epp S; Chuah SM; Halasz M
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069407
[TBL] [Abstract][Full Text] [Related]
27. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
28. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
29. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
Le Clorennec C; Lee K; Huo Y; Zage PE
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
[TBL] [Abstract][Full Text] [Related]
30. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon E; Liang T; Jamin Y; Walz S; Kwok C; Hakkert A; Barker K; Urban Z; Thway K; Zeid R; Hallsworth A; Box G; Ebus ME; Licciardello MP; Sbirkov Y; Lazaro G; Calton E; Costa BM; Valenti M; De Haven Brandon A; Webber H; Tardif N; Almeida GS; Christova R; Boysen G; Richards MW; Barone G; Ford A; Bayliss R; Clarke PA; De Bono J; Gray NS; Blagg J; Robinson SP; Eccles SA; Zheleva D; Bradner JE; Molenaar J; Vivanco I; Eilers M; Workman P; Lin CY; Chesler L
J Clin Invest; 2020 Nov; 130(11):5875-5892. PubMed ID: 33016930
[TBL] [Abstract][Full Text] [Related]
31. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
[TBL] [Abstract][Full Text] [Related]
32. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
33. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
34. Potential anti-neuroblastoma agents from Juniperus oblonga.
Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
[TBL] [Abstract][Full Text] [Related]
35. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
36. Genomic occupancy of the transcriptional co-activators p300 and CBP.
Holmqvist PH; Mannervik M
Transcription; 2013; 4(1):18-23. PubMed ID: 23131664
[TBL] [Abstract][Full Text] [Related]
37. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
38. Computational insights into the binding mode of curcumin analogues against EP300 HAT domain as potent acetyltransferase inhibitors.
Kandagalla S; Shekarappa SB; Rimac H; Grishina MA; Potemkin VA; Hanumanthappa M
J Mol Graph Model; 2020 Dec; 101():107756. PubMed ID: 32979659
[TBL] [Abstract][Full Text] [Related]
39. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
Attar N; Kurdistani SK
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27881443
[TBL] [Abstract][Full Text] [Related]
40. Loss of p300 and CBP disrupts histone acetylation at the mouse Sry promoter and causes XY gonadal sex reversal.
Carré GA; Siggers P; Xipolita M; Brindle P; Lutz B; Wells S; Greenfield A
Hum Mol Genet; 2018 Jan; 27(1):190-198. PubMed ID: 29145650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
